How would you react if PP405 isn't successful in phase 3 trials? Chat 12/8/2025
People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Will Breezula simply be an overhyped flop?
Breezula is seen as potentially overhyped, with concerns about its cost, effectiveness, and long-term benefits compared to existing treatments like finasteride and minoxidil. Some users believe it could complement existing treatments, while others are skeptical about its impact and prefer waiting for newer options like GT20029 and PP405.
community July 1st - Early H2 - Breezula
Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.
community Pelage Pharmaceuticals Phase 3 Trials for PP405 Start in September 2026
Pelage Pharmaceuticals is starting Phase 3 trials for PP405 in September 2026, with potential market release by 2030. Users discuss various hair loss treatments like minoxidil, finasteride, RU58841, kx, breezula, and gt20029, expressing hope for future hair restoration.
community Sooo whens the next big thing gonna come?
New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.
community What new hair-loss treatments actually look exciting right now (Oct 2025)
New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.
Related Research
6 / 6 results
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research Recent Advances in Drug Development for Hair Loss
This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
research Emerging pharmacotherapies for Androgenetic Alopecia
This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.
research Beyond Minoxidil: Off-Label Therapies for Male Androgenetic Alopecia—A Systematic Review with Network Meta-Analyses
In this network meta-analysis, the researchers reported that topical minoxidil 5% was the most effective off-label therapy for increasing hair density in men with androgenetic alopecia, while other treatments like melatonin and cetirizine showed potential benefits, highlighting a need for further comparative trials.
research PP405 in Alopecia: An Emerging Molecule worth Investigating
In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.
research Diagnostic Comparison: SH‑1 Molecule vs PP405 — Safety Profiles in Hair Science
This infographic compares the safety profiles of SH‑1, a cosmetic ingredient, which showed no systemic absorption, and PP405, an investigational drug with dose-dependent systemic uptake and potential threshold breaches, highlighting differences in safety between cosmetic and investigational substances according to this report.